Global leader in genomics-based testing, Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF), has appointed experienced chief financial officer (CFO) Kathryn Andrews as its CFO and company secretary, effective today. ASX and Nasdaq expertise Andrews is a highly experienced biotechnology executive who has been active in ASX and Nasdaq companies, most recently as CFO for Alterity Therapeutics Ltd between November 2014 and February 2024. Prior to this, Andrews held a senior role with The CFO Solution, a firm focused on delivering an outsourced CFO team, including company secretarial to listed public companies, mainly in the biotechnology sector. Earlier, between 2002 and 2006, Andrews was the CFO and company secretary of Antisense Therapeutics Ltd. CEO Simon Morriss said: “We are delighted to have Kathryn join our team and with her extensive experience within our industry and both ASX and Nasdaq expertise, we have no doubt she will add tremendous value to our team.”
This content was originally published here.
